FoundMyFitness · 2026-07-22 · Rhonda Patrick (host), Derya Unutmaz

Why the Next 10 Years May Add 50 to Your Lifespan | Dr. Derya Unutmaz

42 research-tied claims examined: 2 contradicted 3 overstated 4 context 29 supported 2 corroborated online 2 unverified

Overstated

GLP-1 receptor agonists add approximately 5 to 10 years to the lifespan of people who are obese or have chronic conditions.

"Or we're already starting to see that with the GLP-1 drugs, receptor agonists, which are adding about 5 to 10 years to the lifespan of people who are obese or who have chronic conditions." (said at 0:05:15)

GLP-1 receptor agonists (such as semaglutide and liraglutide) have been shown in large randomized clinical trials to significantly reduce all-cause mortality and major adverse cardiovascular events in individuals with obesity, diabetes, and established cardiovascular disease. However, the claim that they add 5 to 10 years to lifespan is substantially overstated. Actuarial modeling applying trial data (such as from the SELECT trial) to real-world populations projects average life expectancy gains of approximately 1.9 years (and ~2.0 cardiovascular event-free years), rather than 5 to 10 years.

partial: Projected life-year gains with semaglutide in individuals with cardiovascular disease with… (Endocrine connections 2026)
"In total, 19,117 individuals aged ≥45 years were included in the main analysis (63% men; mean age: 65.4 years). The estimated gain in life expectancy with semaglutide treatment was 1.9 years. A CV event-free life-year gain of 2.0 years was predicted with semaglutide." (abstract, results, passage verified)
pubmed full study (doi)

0:16:26 Derya Unutmazoverstatedlow

Self-driving cars are currently about 10 times safer than human drivers.

"And right now, self-driving cars are probably about 10 times safer, they will be maybe 100 times safer" (said at 0:16:26)

The speaker claims that self-driving cars are currently "about 10 times safer" than human drivers. Real-world safety assessments of fully autonomous vehicles (such as Waymo's Rider-Only operations) show statistically significant reductions in crash and injury rates compared to human benchmarks, but not by a factor of 10. For example, analysis of 7.14 million miles of Waymo autonomous driving reported an 80% reduction in any-injury-reported crash rates (a human crash rate 5 times higher, or ADS 5 times safer) and a 55% reduction in police-reported crash rates (2.2 times higher human rate). Analysis across 56.7 million miles demonstrated significant reductions across crash types (such as a 91% to 96% reduction in specific vehicle-to-vehicle intersection crashes), but overall safety across all conditions and operations is not 10 times safer than human drivers. Thus, the claim overstates the current safety advantage.

partial: Comparison of Waymo rider-only crash data to human benchmarks at 7.1 million miles (Traffic Injury Prevention 2024) · cited 41x in the literature
"When considering all locations together, the any injury reported crashed vehicle rate was 0.6 incidents per million miles (IPMM) for the ADS vs. 2.80 IPMM for the human benchmark, an 80% reduction or a human crash rate that is 5 times higher than the ADS rate. Police-reported crashed vehicle rates for all locations together were 2.1 IPMM for the ADS vs. 4.68 IPMM for the human benchmark, a 55% reduction or a human crash rate that was 2.2 times higher than the ADS rate." (abstract, results, passage verified)
openalex full study (doi)
partial: Comparison of Waymo Rider-Only crash rates by crash type to human benchmarks at 56.7 milli… (Traffic Injury Prevention 2025) · cited 26x in the literature
"Data were examined over 56.7 million RO miles through the end of January 2025; resulting in a statistically significant lower crashed vehicle rate for all crashes compared to the benchmarks in Any-Injury-Reported and Airbag Deployment, and Suspected Serious Injury + crashes." (abstract, results, passage verified)
openalex full study (doi)

2:06:33 Derya Unutmazoverstatedhigh

Partial epigenetic reprogramming clinical trials are being conducted in patients with glaucoma.

"Like this partial reprogramming trial they're doing, it's it's done for glaucoma patients, I I guess, uh, because that happens in old age, right?" (said at 2:06:33)

The claim that partial epigenetic reprogramming clinical trials are currently being conducted in human patients with glaucoma overstates the clinical progress of this research. Partial epigenetic reprogramming (using Oct4, Sox2, and Klf4, or OSK gene therapy) has shown success in restoring vision in animal models (mice and non-human primates) of glaucoma and optic nerve injury. However, as of recent reviews, these therapies remain in preclinical development, and human clinical trials in glaucoma patients have not yet been conducted.

supports: Reprogramming to recover youthful epigenetic information and restore vision. (Nature 2020) · cited 854x in the literature
"Using the eye as a model CNS tissue, here we show that ectopic expression of Oct4 (also known as Pou5f1), Sox2 and Klf4 genes (OSK) in mouse retinal ganglion cells restores youthful DNA methylation patterns and transcriptomes, promotes axon regeneration after injury, and reverses vision loss in a mouse model of glaucoma and in aged mice." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Emerging role of epigenetic mechanisms in glaucoma and their translational potential. (Frontiers in genetics 2026) · cited 1x in the literature
"Although promising, the current evidences are largely preclinical and long-term human data are still lacking." (abstract, results, passage verified)
pubmed full study (doi)

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.